Proshares UltraPro NASDAQ Biotechnology
UBIO
UBIO was delisted on the 27th of March, 2020.
4 hedge funds and large institutions have $655K invested in Proshares UltraPro NASDAQ Biotechnology in 2017 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 3 closing their positions.
734% more call options, than puts
Call options by funds: $1.79M | Put options by funds: $215K
1.02% less ownership
Funds ownership: 2.67% → 1.65% (-1%)
33% less funds holding
Funds holding: 6 → 4 (-2)
46% less capital invested
Capital invested by funds: $1.22M → $655K (-$561K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$47.3K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
+$43.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$355K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$262K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$73K |
| 4 |
CG
Cutler Group
San Francisco,
California
|
-$48.6K |
| 5 |
Morgan Stanley
New York
|
-$2.81K |
UBIO Hedge Fund Activity: Q2 2017 in Review
4 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Proshares UltraPro NASDAQ Biotechnology (UBIO) for Q2 2017, worth a combined $655K — down 46% from $1.22M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of UBIO and 1 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $47.3K. The largest seller was Virtu Financial, exiting entirely with an estimated $355K sold.
- 4 institutional investors held Proshares UltraPro NASDAQ Biotechnology (UBIO) as of Q2 2017, down from 6 in Q1 2017.
- Funds reported $655K of Proshares UltraPro NASDAQ Biotechnology stock for Q2 2017, down 46% quarter-over-quarter.
- 1 fund opened new Proshares UltraPro NASDAQ Biotechnology positions in Q2 2017 and 3 closed out, a net change of -2 holders.
- The largest Proshares UltraPro NASDAQ Biotechnology buyer in Q2 2017 was Tower Research Capital (TRC), an estimated $47.3K added.
- The largest Proshares UltraPro NASDAQ Biotechnology seller in Q2 2017 was Virtu Financial, an estimated $355K sold.
Based on aggregated 13F filings for Q2 2017.